Clinical Research Workshop - Stars at Night Ballroom 1&2
Moderator: Aditya Bardia, MD, MPH
Massachusetts General Hospital
Boston, MA

Use of the postneoadjuvant setting to accelerate drug development
Melinda Telli, MD
Stanford University School of Medicine
Stanford, CA

How to measure and improve drug adherence in clinical trials
Dawn L. Hershman, MD, MS
Columbia University Medical Center
New York, NY

Statistical considerations for precision medicine
Nabihah Tayob, PhD
Dana-Farber Cancer Institute
Boston, MA

Bringing trials to all patients: A patient's perspective
Thelma Perry Brown, BSc
University of Alabama at Birmingham
Birmingham, AL

Basic Science Workshop - Stars at Night Ballroom 3&4
Moderator: Alana L. Welm, PhD
University of Utah
Salt Lake City, UT

APOBEC and genome evolution in mBC
Reuben S. Harris, PhD
UT Health San Antonio
San Antonio, TX

Therapy-induced senescence: Friend or foe?
Sheila Stewart, PhD
Washington University
St. Louis, MO

Drug-tolerant persister cells in cancer
Joan S. Brugge, PhD
Harvard Medical School
Boston, MA

Clinical implications of tumor heterogeneity single cell genomics
Nnennaya Kanu, PhD
University College London, Cancer Institute
London, United Kingdom

EDUCATIONAL SESSION BLOCK #1A - Stars at Night Ballroom 3&4
Living with Metastatic Breast Cancer
Moderator: Anne Blaes, MD, MSc
University of Minnesota
Minneapolis, MN  

Early palliative care
Tara L. Kaufmann, MD, MSCE
Dell Medical School
University Of Texas at Austin
Austin, TX

Support for patients with MBC
Abbey Kaler, NP
UT MD Anderson Cancer Center
Houston, TX

Financial Toxicity
Fumiko Chino, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Patient Perspective
Christine Hodgdon, MS
GRASP - Guiding Researchers & Advocates to Scientific Partnerships
Baltimore, MD

Stephanie Walker, BSN
MBC Alliance
Tarboro, NC

EDUCATIONAL SESSION BLOCK #1B - Hemisfair Ballroom 1&2
Local Therapy - Best Breast Practice
Moderator: Peter Dubsky, MD, PhD
Breast Center Hirslanden Klinik St. Anna
Luzem, Switzerland

Contralateral mastectomy in patients with germline mutations
Katharine A. Yao, MD
Northshore University HealthSystem
Evanston, IL

RT: How short can it be
David Krug, Dr Med
Universitätsklinikum Schleswig-Holstein
Kiel, Germany

How to reconcile novel reconstructive techniques with the need to radiate
Christine Solbach, MD, PhD
University Hospital Frankfurt
Frankfurt, Germany

EDUCATIONAL SESSION BLOCK #1C - Hemisfair Ballroom 3
New Agents Targeting HRD in Breast Cancer
Moderator: Erica Stringer-Reasor, MD
University of Alabama at Birmingham
Birmingham, AL

Pol-theta inhibitors in HRD tumors
Alan D. d'Andrea, MD
Dana-Farber Cancer Institute
Boston, MA

Mechanisms of sensitivity and resistance to HRD targeting agents in breast cancer - PARPi and beyond
Christopher Lord, DPhil
Institute of Cancer Research
London, United Kingdom

ATR inhibitors and PARP1 selective PARP inhibitors
Andrew Tutt, MB ChB, PhD
Institute of Cancer Research
London, United Kingdom

EDUCATIONAL SESSION BLOCK #1D - Stars at Night Ballroom 1&2
Predictive Value of Treatment Response and Residual Disease After Neoadjuvant Therapy
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

ER therapies
Cynthia X. Ma, MD, PhD
Washington University in St. Louis
St. Louis, MO

HER2
Luca Gianni, MD
Fondazione Michelangelo
Milano, Italy

Triple Negative
Peter Schmid, MD, PhD, FRCP
Bart's Cancer Institute
London, United Kingdom

SPECIAL SESSION #1 - Stars at Night Ballroom 1&2
Big Data and Health Equity
Moderators: Thelma Brown, BSc
University of Alabama at Birmingham
Birmingham, AL

Maimah Karmo, BS
Tigerlily Foundation
Aldie, VA

Charles Perou, PhD
University of North Carolina
Chapel Hill, NC

Patty Spears, BS
UNC Patient Advocates for Research Council
Chapel Hill, NC

Keynote Speakers:
Martin Mendoza, PhD
National Institutes of Health
Bethesda, MD

Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico

Panelists:
Rhea Blakey
FDA
Silver Spring, MD

Michael Crawford, MBA, MHLA
Howard University
Washington, DC

Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN

Martin Mendoza, PhD
National Institute of Health
Bethesda, MD

Charlotte Owens, MD
Takeda Pharmaceutical Company
Cambridge, MA

Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico

Jasmine Souers, BSc
The Missing Pink Breast Cancer Alliance
Jackson, FL

SPECIAL SESSION #2 - Hall 3
Tackling the Big Questions in Breast Cancer?
Chairs:
Carlos Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
and
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

Panelists:
Christine Ambrosone, PhD
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Fabrice André, MD, PhD
Gustave Roussy
Villejuif, France

Regina Barzilay, PhD
Massachusetts Institute of Technology
Cambridge, MA

Joan S. Brugge, PhD
Harvard Medical School
Boston, MA

Matthew J. Ellis, MD, PhD
AstraZeneca
Gaithersburg, MD

Nadia Harbeck, MD, PhD
LMU University Hospital
Munich, Germany

Yeon Hee Park, MD, PhD
Samsung Medical Center
Seoul, South Korea

Lori Pierce, MD
University of Michigan
Ann Arbor, MI

Patty Spears, BS
UNC Patient Advocates For Research Council
Chapel Hill, NC

Eric Winer, MD
Yale Cancer Center
New Haven, CT

POSTER SESSION #2 - Hall 1

MINI-SYMPOSIUM #1 - Hall 3
C. Kent Osborne HER2 and ER Crosstalk: Signaling Mechanisms and Clinical Implications Symposium
Moderator: Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
and
Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Special Guest: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

HER2 signaling the ER cistrome
Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

Oncogene signal transduction and antiestrogen resistance
Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Treatment of ER+/HER2+ breast cancer
Stephen Johnston, MBBS
The Royal Marsden Hospital
London, United Kingdom

CAREER DEVELOPMENT FORUM - Room 304

CLINICAL CASE DISCUSSION SESSION - Stars at Night Ballroom 1&2
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Panelist:
Michael Gnant, MD, FACS, FEBShon
Medical University of Vienna
Vienna, Austria

Celina Kleer, MD
University of Michigan Medical School
Ann Arbor, MI

Julia Maues
GRASP
Washington, DC

George Sledge, Jr, MD
Stanford University
Stanford, CA

Jonathan Strauss, MD
Northwestern
Chicago, IL

Shaveta Vinayak, MD
University of Washington
Seattle, WA

FORUM #1 - Stars at Night Ballroom 3&4
Molecular Aspects of DCIS Progression
Moderator: E. Shelley Hwang, MD, MPH
Duke University
Durham, NC

Tumor stroma in DCIS progression
Robert West, MD, PhD
Stanford University Medical Center
Stanford, CA

Clonal evolution of DCIS to invasion
Jelle Wesseling, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands

Defining clinical risk: How do we tailor therapy
Kimberly J. Van Zee, MS, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY

CLINICAL CONTROVERSIES - Hall 3
Moderator: Lisa Carey, MD, ScM, FASCO
UNC-Lineberger Comprehensive Cancer Center
Chapel Hill, NC

To clip or not to clip
Abigail Caudle, MD
UT MD Anderson Cancer Center
Houston, TX
and
Viviana E. Galimberti, MD, MPH
European Institute of Oncology
Milan, Italy

Duration of endocrine therapy
Kathryn Ruddy, MD, PhD
Mayo Clinic
Rochester, MN
and
Eleftherios (Terry) Mamounas, MD, MSc
Orlando Health Cancer Institute
Orlando, FL

Post Neoadjuvant therapy in TNBC
Heather McArthur, MD, MPH
UT Southwestern
Dallas, TX
and
Susan Domchek, MD
University of Pennsylvania School of Medicine
Philadelphia, PA

MINI-SYMPOSIUM #2 - Stars at Night Ballroom 1&2
Late Recurrence and Tumor Dormancy
Moderator: Alana Welm, PhD
Masonic Cancer Center
University of Minnesota
Minneapolis, MN

NK cell induced dormancy
Ana Luisa Correia, PhD
Champalimaud Research
Lisboa, Portugal

Extra cellular matrix and dormancy
Javier Bravo-Cordero, PhD
Icahn School of Medicine
New York, NY

Implications for clinical care
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

FORUM #2 New Targets and Strategies for Immunotherapy - Stars at Night Ballroom 3&4
Moderator: Justin Balko, PhD
Vanderbilt University Medical Center
Nashville, TN

Activating a collaborative innate-adaptive immune
response to control metastasis
Mikala Egeblad, PhD
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY

Neutrophil elastase and anti-tumor effects
Lev Becker, PhD
University of Chicago
Chicago, IL

Immunosuppressive macrophages and PARP inhibitor resistance
Jennifer Guerriero, PhD
Brigham and Women's Hospital
Boston, MA

EDUCATIONAL SESSION BLOCK #2

EDUCATIONAL SESSION BLOCK #2A - Hemisfair Ballroom 1&2
Digital Health and PROs in Breast Cancer Research and Care
Moderator: Ann H. Partridge, MD, MPH
Dana Farber Institute
Boston, MA

What are PROs and evidence for benefit?
Shoshana Rosenberg, ScD, MPH
Weill Cornell Medicine
New York, NY

How to incorporate PROs into clinical care
Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Where are we going with digital interventions and PROs
Ines Vaz Luis, PhD
Gustave Roussy
Villejuif, France

Patient Advocate Perspective
Patty Spears, BS
UNC Patient Advocates for Research Council
Chapel Hill, NC

EDUCATIONAL SESSION BLOCK #2B - Stars at Night Ballroom  1&2
Antibody Drug Conjugates: Future Directions and Opportunities
Moderator: Ian E. Krop, MD, PhD
Yale School of Medicine
New Haven, CT

Bioengineering and mechanism of action of ADC
Puja Sapra, PhD
AstraZeneca
New York, NY

ADCs in breast oncology: Present and future
Shanu Modi, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Mechanisms of resistance
Leif Ellison, MD, PhD
Massachusetts General Hospital
Boston, MA

EDUCATIONAL SESSION BLOCK #2C - Stars at Night Ballroom 3&4

Spatial and Single Cell Characterization of Breast Cancer - Progression 
Moderator: Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA

Single cell profiling
Alex Swarbrick, PhD
Garvan Institute of Medical Research
Darlinghurst, Australia

Multiplex spatial proteomic profiling
David Rimm, MD, PhD
Yale University
New Haven, CT

Imaging mass cytometry of breast cancer
Raza Ali, MD, FRCPC, MSc
Cancer Research UK Cambridge Institute
Cambridge, United Kingdom

Beyond the lab: Clinical implications
Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA

EDUCATIONAL SESSION BLOCK #2D - Hemisfair Ballroom 3
Breast Cancer and Cardiovascular Toxicity: What an Oncologist Needs to Know
Co-Moderator: Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO
and Co-Moderator: Susan Dent, MD
Duke
Durham, NC

Beyond anthracyclines and trastuzumab: Cardiotoxicity of new novel agents
Susan Dent, MD
Duke
Durham, NC

Radiation therapy and cardiovascular disease in breast cancer
Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO

Cardiovascular toxicity and breast cancer: Detection and prevention strategies
Dinesh Thavendiranathan, MD, MSc
Peter Munk Cardiac Center, Toronto General Hospital, University of Toronto
Toronto, Canada

Cardiac problems secondary to chemotherapy
Alexea Gaffney, MD
Stony Brook Medicine
Stony Brook, NY

POSTER SESSION #4 - Hall 1

DEBATE Are all of CDK4/6 Inhibitors the Same or Different?- Hall 3

PLENARY LECTURE #2 - Hall 3

Premenopausal ER+ Breast Cancer: Past, Present, and Future
Prudence Francis, MD
Peter MacCullum Cancer Centre
Victoria, Australia

MOLECULAR TUMOR BOARD - Stars at Night Ballroom 1&2
Moderator: Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milano, Italy

Panelist:

Philippe Aftimos, MD
Institut Jules Bordet
Brussels, Belgium

Philippe Bedard, MD
Princess Margaret Cancer Centre
Toronto, Canada

Amy L. Delson
University of California San Francisco
Atherton, CA

Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN

Sara Hurvitz, MD, FACP
University of California San Francisco
Los Angeles, CA

Aleix Prat, MD, PhD
Hospital Clinic Barcelona
Barcelona, Spain

Daniel Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH

FORUM #3 - Stars at Night Ballroom 3&4
Modifying Tumor Response: Microbiome, Diet, and Fasting
Moderator: Sangeetha Reddy, MD, MSc
UT Southwestern Medical Center
Dallas, TX

Fungal regulation of breast tumor radiation response
Stephen L. Shiao, MD, PhD
Cedars-Sinai
Los Angeles, CA

Microbiome and response to immunotherapy
Jennifer A. Wargo, MD
UT MD Anderson Cancer Center
Houston, TX

Fasting and Microbiotic
Guido Kroemer, MD, PhD, PU-PH
University of Paris Descartes
Paris, France

TRANSLATIONAL CONTROVERSIES - Stars at Night Ballroom 1&2
Moderator: Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center
New York, NY

RIP MTD
Hope S. Rugo, MD, FASCO
University of California San Francisco
San Francisco, CA

Geoffrey Shapiro, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Randomized trials vs real world evidence
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

Sean Khozin, MD, MPH
CancerLinQ, LLC
New York, NY

Ki 67
Nadia Harbeck, MD, PhD
LMU University Hospital
Munich, Germany

Torsten Nielsen, MD, PhD, FRCPC
University of British Columbia
Vancouver, Canada

FORUM #4 - Stars at Night Ballroom 3&4
Demystifying CDKs in Breast Cancer: Beyond CDK4/6
Moderator: Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

CDK4/6 inhibitor resistance: Biological mechanisms and novel approaches
Ariella Hanker, PhD
UT Southwestern Medical Center
Dallas, TX

Current status of CDK2 inhibitors in (pre-)clinical development
Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Inhibiting transcriptional CDKs in breast cancer
Charles Coombes, MD, PhD
Imperial College
London, United Kingdom

EDUCATIONAL SESSION BLOCK #3

EDUCATIONAL SESSION BLOCK #3A - Hemisfair Ballroom 1&2
Management of Hereditary Risk: Moderate-Risk Genes and New Approaches
Moderator: Seema A. Khan, MD
Northwestern University
Chicago, IL

Cancer risks in patients with high penetrance gene mutations
Payal D. Shah, MD
Penn Medicine
Philadelphia, PA

Screening for high-risk patients: Does everyone need annual MRI with mammogram?
Madeleine M.A. Tilanus-Linthorst, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands

Hormonal exposure and risk in BRCA1/2 carriers
Joanne Kotsopoulos, MSc, PhD
University of Toronto
Toronto, Canada

EDUCATIONAL SESSION BLOCK #3B - Stars at Night Ballroom 1&2
Challenging Types of Breast Cancer 
Moderator: Bora Lim, MD
Baylor College of Medicine
Houston, TX

Pathologic aspects
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Metaplastic
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston, Salem, NC

Inflammatory
Filipa Lynce, MD
Dana-Farber Cancer Institute
Boston, MA

Lobular/pleomorphic
Sibylle Loibl, MD, PhD
German Breast Group
Neu-isenburg, Germany

EDUCATIONAL SESSION BLOCK #3C - Stars at Night Ballroom 3&4
What ctDNA Can Tell Us
Moderator: Nicholas Turner, PhD, FRCP
The Royal Marsden Hospital
London, United Kingdom

Which is the best technique
Heather Parsons, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Can ctDNA substitute tissue testing
Ben O'Leary, MBBS, PhD
The Institute of Cancer Research
London, United Kingdom

Using ctDNA in detecting disease
Minetta C. Liu, MD
Mayo Clinic
Rochester, MN

POSTER SESSION #6 - Hall 1

SPOTLIGHT POSTER DISCUSSOIN SESSION#16 Imaging to Diagnose Breast Cancer and Direct Its Treatment: Who, When, and How? - Hemisfair Ballroom 1&2
SPOTLIGHT POSTER DISCUSSION SESSION #17 Endocrine Therapy New Insights - Stars at Night Ballroom 1&2
SPOTLIGHT POSTER DISCUSSION SESSION #18 Updates and New Therapies for HER2 Positive Disease - Stars at Night Ballroom 3&4

BREAK 

EDUCATIONAL SESSION BLOCK #4

EDUCATIONAL SESSION BLOCK #4A - Stars at Night Ballroom 1&2
Advances in Pregnancy Associated Breast Cancer (PABC)
Moderator: Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Updates in the pathology of PABCS
Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Special treatment issues in this young patient population
Ann Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Oncofertility and other quality of life issues
Matteo Lambertini, MD, PhD
University of Genova - San Martino Hospital
Genova, Italy

EDUCATIONAL SESSION BLOCK #4B - Stars at Night Ballroom 3&4
State of the Art Radiotherapy: Reducing Toxicity and Increasing Options
Moderator: Wendy Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

The role of advanced radiation technology in reducing toxicity
Rachel Jimenez, MD
Massachusetts General Hospital
Boston, MA

Overview of the current state of the art - what patients and oncologists need to know
Melissa Mitchell, MD, PhD
UT MD Anderson Cancer Center
Houston

Evidence for ablative radiation in metastatic breast cancer
Chiaojung Jillian Tsai, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

EDUCATIONAL SESSION BLOCK #4C - Hemisfair Ballroom 1&2
Targeting the Tumor Microenvironment for Clinical Impact
Moderator: Diana Cittelly, PhD
University of Colorado Anschutz Medical Campus
Aurora, CO

Influence of bone microenvironment on metastasis
Igor Bado, PhD
Baylor College of Medicine
Houston, TX

The contribution of the tumor microenvironment to cancer dormancy
J. Javier Bravo-Cordero, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Effects of age on the tumor microenvironment
Sandra S. McAllister, PhD
Harvard Institutes of Medicine
Boston, MA

Can inflammation be targeted?
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

REFRESHMENT BREAK

View from the Trenches: What will You do on Monday Morning - Stars at Night Ballroom 1&2
Co-Moderator: Andrea Barrio, MD
Co-Moderator: Sara Tolaney, MD, MPH

Panel Members
Vernal Branch
Patient Advocate
UNC Chapel Hill Lineberger Cancer Institute
Mooresville, NC

Marianna Chavez, MD, MSC, FASCO

Tanja N. Fehm, MD
University Hospital
Düsseldorf
Düsseldorf, Germany

Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Mediget Teshome, MD, MPH, FACS
UT MD Anderson Cancer Center
Houston, TX 

Cynthia Villareal Garza, MD, DSc
Tecnológico de Monterrey
Monterrey, Mexico

Richard C. Zellars, MD
Indiana University
Indianapolis, IN

Moderators: Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
and
Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Basic science
Andrei Goga, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Translational research
Shom Goel, MBBS, B Med Sci (Hons)
Peter MacCallum Cancer Centre
Melbourne, Australia

Early breast cancer
Marleen Kok, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands

Advanced breast cancer
Melinda Telli, MD
Stanford University School of Medicine
San Francisco, CA